Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature
Articolo
Data di Pubblicazione:
2019
Citazione:
Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature / Grisanti, Salvatore; Ferrari, Vittorio Domenico; Buglione Di Monale E Bastia, Michela; Agazzi, Giorgio M; Liserre, Roberto; Poliani, Pietro Luigi; Buttolo, Luciano; Gipponi, Stefano; Pedersini, Rebecca; Consoli, Francesca; Panciani, Pierpaolo; Roca, Elisa; Spena, Giannantonio; Triggiani, Luca; Berruti, Alfredo. - In: JOURNAL OF NEUROSURGICAL SCIENCES. - ISSN 0390-5616. - 63:4(2019), pp. 458-467. [10.23736/S0390-5616.16.03874-1]
Abstract:
Second line treatment of recurrent or progressive glioblastoma multiforme (GBM) is not standardized. Anti-angiogenic strategies with tyrosine-kinase inhibitors have been tested with conflicting results. We tested the association of sunitinib (S) plus irinotecan (CPT-11) in a phase II trial in terms of response rate (RR) and 6-months progression-free survival (6-PFS). We also reviewed the clinical evidence from all the trials with S in this setting published to date and summarized it in a meta-analysis.
Tipologia CRIS:
1.1.1 Articolo in rivista - Review
Elenco autori:
Grisanti, Salvatore; Ferrari, Vittorio Domenico; Buglione Di Monale E Bastia, Michela; Agazzi, Giorgio M; Liserre, Roberto; Poliani, Pietro Luigi; Buttolo, Luciano; Gipponi, Stefano; Pedersini, Rebecca; Consoli, Francesca; Panciani, Pierpaolo; Roca, Elisa; Spena, Giannantonio; Triggiani, Luca; Berruti, Alfredo
Link alla scheda completa:
Pubblicato in: